-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 24th National Conference on Clinical Oncology and the 2021 CSCO Annual Conference will be held on September 25-29, 2021.
The theme of this conference is "Focus on Innovative Research, Leading the Original Future"
.
At the CSCO conference, Professor Zhu Jun from Peking University Cancer Hospital introduced an ongoing antibody-drug conjugate loncastuximab tesirine (lonca) for the treatment of Chinese patients with relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL) II Period research
.
Yimaitong has the honor to invite Professor Zhu Jun to share the application prospects of new drugs in R/R DLBCL
.
Yimaitong: In recent years, there have been many new drugs and new therapies in the treatment of R/R DLBCL.
Could you please introduce what new drugs and new therapies are worth paying attention to in the treatment of R/R DLBCL? Professor Jun Zhu R/R DLBCL is currently the main indication for the research and development of new drugs for lymphoma
.
Due to the large number of R/R DLBCL patients, and the current treatment options for R/R DLBCL patients are relatively limited, many clinical studies are exploring the efficacy of new drugs and new therapies in R/R DLBCL
.
The R/R DLBCL-related research currently being carried out on a global scale mainly includes three types of drugs and therapies
.
The first is antibody drugs: monoclonal antibodies include anti-CD20 monoclonal antibodies, anti-CD19 monoclonal antibodies, etc.
, among which a new generation of anti-CD20 monoclonal antibody otuzumab was approved for marketing in China this year; antibody-drug conjugates included last year in China The approved vebutuximab has completed the report of new drug clinical trial data and is waiting for approval of Polatuzumab vedotin (Pola).
The initial clinical trial of the antibody drug conjugate loncastuximab tesirine (lonca) introduced at the CSCO conference is also Demonstrated good efficacy and safety; among the bispecific antibodies, a variety of bispecific antibodies targeting CD19/CD3 and CD20/CD3 have also carried out relevant clinical trials at home and abroad
.
Secondly, there are currently many studies exploring the efficacy of small molecule drugs in R/R DLBCL around the world.
These studies cover proteasome inhibitors, histone deacetylase inhibitors, BTK inhibitors, PI3K inhibitors and other drugs.
The therapeutic prospects of related small molecule drugs in R/R DLBCL are also worth looking forward to
.
In addition, cellular immunotherapy is also the current research focus of R/R DLBCL
.
Two types of chimeric antigen receptor T cell (CAR-T) immunotherapies have recently been approved in China for the treatment of R/R DLBCL, bringing hope of cure for the majority of R/R DLBCL patients
.
Our clinicians must first reasonably use these new drugs and new therapies to bring better prognosis for patients with R/R DLBCL
.
On the other hand, we also need to further develop more new drugs and new therapies to explore better treatment options for patients with R/R DLBCL
.
At present, the treatment of R/R DLBCL has entered a new era in which new drugs are constantly emerging.
We need to contribute our efforts to this trend to develop better new drugs and new therapies for R/R DLBCL patients to better serve patients
.
Yimaitong: At this CSCO conference, you introduced a phase II study of lonca in the treatment of R/R DLBCL patients in China.
Could you please introduce the purpose and expected results of the study? Compared with other drugs, what are the advantages of lonca in treating R/R DLBCL? Professor Zhu Jun lonca is an antibody-drug conjugate produced by coupling a monoclonal antibody targeting CD19 with a pyrrolobenzodiazepine dimer (PBD)
.
Lonca can trigger the internalization path into tumor cells by binding to the CD19 antigen, and release PBD after being endocytosed by tumor cells to inhibit the growth of tumor cells and cause tumor cells to kill
.
Although R/R DLBCL has a high level of CD19 expression, the anti-CD19 monoclonal antibody has poor anti-tumor activity in R/R DLBCL
.
Compared with the anti-CD19 monoclonal antibody, the anti-tumor activity of the antibody-drug conjugate Ionca has been significantly improved.
In the phase I ADCT-201-101 study that has been completed, the overall remission rate of lonca monotherapy for R/R DLBCL (ORR) reached 42.
3%, and the complete remission (CR) rate reached 23.
4%
.
Enrollment has been completed.
In the ongoing ADCT-402-201 study, lonca has brought durable disease remission for R/R DLBCL patients.
The median duration of remission (DOR) of 70 patients who achieved disease remission reached 12.
58.
Months, the median DOR of patients who achieved CR reached 13.
37 months
.
The median progression-free survival (PFS) was 4.
93 months, and the median overall survival (OS) was 9.
53 months
.
In related studies, lonca has good safety in the treatment of R/R DLBCL, and the side effects are controllable
.
With the further exploration of the lonca combination plan in the future related research, the ORR of Ionca in the treatment of R/R DLBCL is expected to be further improved
.
lonca was approved by the FDA for the treatment of R/R DLBCL in April this year, and lonca has also been approved for clinical research in China
.
Peking University Cancer Hospital, as the lead unit of the lonca research carried out in China, has now joined nearly 20 centers across the country to enroll patients
.
I look forward to the smooth progress of the research and the acquisition of valuable clinical experience and data, which will lay a solid foundation for the approval of lonca in China in the future
.
At present, we are full of confidence in lonca, and hope that it can bring new hope for treatment to the vast number of R/R DLBCL patients across the country in the future
.
Yimaitong: What are your expectations for the future application prospects of new drugs and new therapies in R/R DLBCL? The emergence of many new drugs and new therapies by Professor Zhu Jun has significantly changed the treatment pattern of R/R DLBCL
.
At present, the drugs and therapies that R/R DLBCL patients are exposed to, both in quantity and quality, are different from those two or thirty years ago
.
However, many new drugs and new therapies have also brought some treatment problems for patients with R/R DLBCL
.
Some new drugs and new therapies are still relatively expensive and poorly accessible to patients
.
I think this problem needs to be combined with the current national conditions and through the efforts of the government, pharmaceutical companies, and hospitals to provide patients with better treatment services
.
If some drugs can enter medical insurance, some companies can provide commercial insurance sponsorship, and some pharmaceutical companies can provide charity assistance, then the availability of drugs for the majority of patients will be greatly improved
.
Of course, in the process of solving the problem of the availability of new drugs, it is also necessary to take into account the factors of new drug R&D and development, take into account the interests of all parties, and provide development space for the research and development of new drugs
.
All in all, as long as all parties can adhere to the goal of life first and people first, the problem of drug accessibility for Chinese patients will gradually be resolved
.
Patients will receive better medical services, and drug research and development will continue to make great progress
.
Professor Zhu Jun, Secretary of the Party Committee of Peking University Cancer Hospital, Director of the Department of Internal Medicine, Director of the Department of Lymphoma, Doctoral Supervisor, mainly focuses on the diagnosis and treatment of malignant lymphoma.
Chairman of the Lymphoma Alliance Member of the Standing Committee of the Geriatric Oncology Committee of the Chinese Society of Gerontology, Member of the Standing Committee of the Chinese Anti-Cancer Association (CACA) of the Professional Committee of Cancer Targeted Therapy, Vice Chairman of the Beijing Anti-Cancer Association, Vice Chairman of the China Human Health Science and Technology Promotion Association, stamp "read the original text", We make progress together
The theme of this conference is "Focus on Innovative Research, Leading the Original Future"
.
At the CSCO conference, Professor Zhu Jun from Peking University Cancer Hospital introduced an ongoing antibody-drug conjugate loncastuximab tesirine (lonca) for the treatment of Chinese patients with relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL) II Period research
.
Yimaitong has the honor to invite Professor Zhu Jun to share the application prospects of new drugs in R/R DLBCL
.
Yimaitong: In recent years, there have been many new drugs and new therapies in the treatment of R/R DLBCL.
Could you please introduce what new drugs and new therapies are worth paying attention to in the treatment of R/R DLBCL? Professor Jun Zhu R/R DLBCL is currently the main indication for the research and development of new drugs for lymphoma
.
Due to the large number of R/R DLBCL patients, and the current treatment options for R/R DLBCL patients are relatively limited, many clinical studies are exploring the efficacy of new drugs and new therapies in R/R DLBCL
.
The R/R DLBCL-related research currently being carried out on a global scale mainly includes three types of drugs and therapies
.
The first is antibody drugs: monoclonal antibodies include anti-CD20 monoclonal antibodies, anti-CD19 monoclonal antibodies, etc.
, among which a new generation of anti-CD20 monoclonal antibody otuzumab was approved for marketing in China this year; antibody-drug conjugates included last year in China The approved vebutuximab has completed the report of new drug clinical trial data and is waiting for approval of Polatuzumab vedotin (Pola).
The initial clinical trial of the antibody drug conjugate loncastuximab tesirine (lonca) introduced at the CSCO conference is also Demonstrated good efficacy and safety; among the bispecific antibodies, a variety of bispecific antibodies targeting CD19/CD3 and CD20/CD3 have also carried out relevant clinical trials at home and abroad
.
Secondly, there are currently many studies exploring the efficacy of small molecule drugs in R/R DLBCL around the world.
These studies cover proteasome inhibitors, histone deacetylase inhibitors, BTK inhibitors, PI3K inhibitors and other drugs.
The therapeutic prospects of related small molecule drugs in R/R DLBCL are also worth looking forward to
.
In addition, cellular immunotherapy is also the current research focus of R/R DLBCL
.
Two types of chimeric antigen receptor T cell (CAR-T) immunotherapies have recently been approved in China for the treatment of R/R DLBCL, bringing hope of cure for the majority of R/R DLBCL patients
.
Our clinicians must first reasonably use these new drugs and new therapies to bring better prognosis for patients with R/R DLBCL
.
On the other hand, we also need to further develop more new drugs and new therapies to explore better treatment options for patients with R/R DLBCL
.
At present, the treatment of R/R DLBCL has entered a new era in which new drugs are constantly emerging.
We need to contribute our efforts to this trend to develop better new drugs and new therapies for R/R DLBCL patients to better serve patients
.
Yimaitong: At this CSCO conference, you introduced a phase II study of lonca in the treatment of R/R DLBCL patients in China.
Could you please introduce the purpose and expected results of the study? Compared with other drugs, what are the advantages of lonca in treating R/R DLBCL? Professor Zhu Jun lonca is an antibody-drug conjugate produced by coupling a monoclonal antibody targeting CD19 with a pyrrolobenzodiazepine dimer (PBD)
.
Lonca can trigger the internalization path into tumor cells by binding to the CD19 antigen, and release PBD after being endocytosed by tumor cells to inhibit the growth of tumor cells and cause tumor cells to kill
.
Although R/R DLBCL has a high level of CD19 expression, the anti-CD19 monoclonal antibody has poor anti-tumor activity in R/R DLBCL
.
Compared with the anti-CD19 monoclonal antibody, the anti-tumor activity of the antibody-drug conjugate Ionca has been significantly improved.
In the phase I ADCT-201-101 study that has been completed, the overall remission rate of lonca monotherapy for R/R DLBCL (ORR) reached 42.
3%, and the complete remission (CR) rate reached 23.
4%
.
Enrollment has been completed.
In the ongoing ADCT-402-201 study, lonca has brought durable disease remission for R/R DLBCL patients.
The median duration of remission (DOR) of 70 patients who achieved disease remission reached 12.
58.
Months, the median DOR of patients who achieved CR reached 13.
37 months
.
The median progression-free survival (PFS) was 4.
93 months, and the median overall survival (OS) was 9.
53 months
.
In related studies, lonca has good safety in the treatment of R/R DLBCL, and the side effects are controllable
.
With the further exploration of the lonca combination plan in the future related research, the ORR of Ionca in the treatment of R/R DLBCL is expected to be further improved
.
lonca was approved by the FDA for the treatment of R/R DLBCL in April this year, and lonca has also been approved for clinical research in China
.
Peking University Cancer Hospital, as the lead unit of the lonca research carried out in China, has now joined nearly 20 centers across the country to enroll patients
.
I look forward to the smooth progress of the research and the acquisition of valuable clinical experience and data, which will lay a solid foundation for the approval of lonca in China in the future
.
At present, we are full of confidence in lonca, and hope that it can bring new hope for treatment to the vast number of R/R DLBCL patients across the country in the future
.
Yimaitong: What are your expectations for the future application prospects of new drugs and new therapies in R/R DLBCL? The emergence of many new drugs and new therapies by Professor Zhu Jun has significantly changed the treatment pattern of R/R DLBCL
.
At present, the drugs and therapies that R/R DLBCL patients are exposed to, both in quantity and quality, are different from those two or thirty years ago
.
However, many new drugs and new therapies have also brought some treatment problems for patients with R/R DLBCL
.
Some new drugs and new therapies are still relatively expensive and poorly accessible to patients
.
I think this problem needs to be combined with the current national conditions and through the efforts of the government, pharmaceutical companies, and hospitals to provide patients with better treatment services
.
If some drugs can enter medical insurance, some companies can provide commercial insurance sponsorship, and some pharmaceutical companies can provide charity assistance, then the availability of drugs for the majority of patients will be greatly improved
.
Of course, in the process of solving the problem of the availability of new drugs, it is also necessary to take into account the factors of new drug R&D and development, take into account the interests of all parties, and provide development space for the research and development of new drugs
.
All in all, as long as all parties can adhere to the goal of life first and people first, the problem of drug accessibility for Chinese patients will gradually be resolved
.
Patients will receive better medical services, and drug research and development will continue to make great progress
.
Professor Zhu Jun, Secretary of the Party Committee of Peking University Cancer Hospital, Director of the Department of Internal Medicine, Director of the Department of Lymphoma, Doctoral Supervisor, mainly focuses on the diagnosis and treatment of malignant lymphoma.
Chairman of the Lymphoma Alliance Member of the Standing Committee of the Geriatric Oncology Committee of the Chinese Society of Gerontology, Member of the Standing Committee of the Chinese Anti-Cancer Association (CACA) of the Professional Committee of Cancer Targeted Therapy, Vice Chairman of the Beijing Anti-Cancer Association, Vice Chairman of the China Human Health Science and Technology Promotion Association, stamp "read the original text", We make progress together
